MSD Bets $510M on High-Quality Data to Fuel Post-Keytruda AI Drug Discovery
MSD, which has long dominated the global cancer market with its blockbuster immuno-oncology therapy Keytruda, is investing heavily in artificial...
Search results for "k-bio"
Kyungpook National University Hospital Establishes Precision Medicine Infrastructure for High-Throughput Proteomic Analysis
Kyungpook National University Hospital is building an advanced research infrastructure capable of profiling thousands of proteins simultaneously from...
Reengineering Your Morning Routine: The Biological Case for Water, Breakfast, and Coffee
What is the very first thing you do when you open your eyes in the morning? While the habit has fortunately declined,...
South Korean Researchers Discover Compound That Destroys Chemo-Resistant Liver Cancer Cells
Cancer cells that no longer respond to chemotherapy present one of the most formidable challenges in oncology.
South Korean Biotechs Race to Conquer the Untapped Global MASH Market
Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.
Osteoporosis Drugs That Can Be Hard to Keep Taking…Could ‘Sleeping Bone Cells’ Offer a Breakthrough?
Some patients need to rebuild bone quickly. These are people at high fracture risk—those who have already broken a bone...
New Biologic Drug Lands in Korea: Expanded Relief for Chronic Rhinosinusitis and Nasal Polyps
A biologic medication previously recognized for its effectiveness in treating severe asthma is now offering a new...
A Milestone for K-Bio: Celltrion’s Truxima Surpasses Global Blockbuster Rituxan in U.S. Prescriptions
Truxima , a blood cancer treatment developed by Celltrion, has become the first Korean-made biosimilar to rank number...
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...
Idience Targeted Cancer Drug Candidate ‘Venadaparib’ Granted FDA Fast Track Designation
Idience, a novel anticancer drug developer under the Ildong Pharmaceutical Group, announced on the 18th that its...